Despite the impact on women’s health worldwide, significant unmet needs exist in the diagnosis and treatment of gynecologic cancers. Located in the female reproductive system, many have a reputation for being “silent,” as they are often detected in later stages when treatment options are limited.
However, the recent introduction of novel medicines — targeted therapies in particular — has led to improvements in patient care and uncovered new research opportunities, creating a competitive research environment. With investment in research on the rise, investigators face challenges in patient identification, site selection and an ever-changing regulatory landscape.
Join Premier Research experts, (Moderator) Mary Gunn, PhD, COO, Women’s Health and Diagnostics; Rupa Doshi, PhD, Vice President, Program Strategy, Oncology; Andrew Berchuck, MD, Medical Advisor, Gynecologic Oncology; and Irene Figari, Senior Director, Regulatory Affairs, Premier Consulting.